Welcome to our dedicated page for Clearside Biomedical news (Ticker: CLSD), a resource for investors and traders seeking the latest updates and insights on Clearside Biomedical stock.
Clearside Biomedical, Inc. (symbol: CLSD) is a prominent clinical biopharmaceutical company based in Alpharetta, Georgia. Specializing in the development of pharmacological therapies, the company's primary focus is on treating blinding diseases of the eye through their innovative suprachoroidal space (SCS) technology.
Clearside Biomedical's cornerstone is their SCS Microinjector®, a proprietary device that facilitates a non-surgical, office-based procedure. This technology allows for targeted delivery of therapies directly to the macula, retina, or choroid, which could potentially preserve and enhance vision for patients suffering from severe eye conditions.
One of the company's significant achievements is the robust safety profile and encouraging efficacy data from multiple studies using the SCS Microinjector®. These findings have been featured in numerous oral and poster presentations, highlighting the potential of Clearside’s technology in ophthalmic therapeutics.
Clearside Biomedical continues to advance its pipeline of ophthalmic therapies, collaborating with various partners to bring innovative treatments to market. The company remains committed to improving the quality of life for individuals with vision-threatening diseases through groundbreaking research and development.
Recent Achievements:
- Clinical data utilizing Clearside’s suprachoroidal delivery technology featured in multiple presentations.
- Enhanced safety and efficacy data presented, showcasing the utility of the SCS Microinjector®.
Investors and media can reach out to Jenny Kobin and Remy Bernarda for more information at ir@clearsidebio.com or by calling (678) 430-8206.
Clearside Biomedical (Nasdaq: CLSD) has announced key findings from poster presentations at the ARVO 2023 Annual Meeting, showcasing its suprachoroidal injection delivery platform. The data presented highlighted the effectiveness of SCS delivery of small molecule suspensions, leading to targeted and durable drug delivery to the chorioretina. Notably, the Phase 1/2a OASIS trial of CLS-AX (axitinib injectable suspension) in wet AMD patients indicated a 77%-85% reduction in treatment burden along with an excellent safety profile. Additionally, the survey on the early adoption of XIPERE showed positive responses from retinal specialists regarding its ease of use and effectiveness. Clearside plans to initiate the randomized Phase 2b ODYSSEY trial for CLS-AX soon, signaling potential growth and development in retinal disease treatments.
Clearside Biomedical, Inc. (Nasdaq: CLSD) announced multiple poster presentations for its suprachoroidal injection delivery platform at the ARVO 2023 Annual Meeting, occurring from April 23-27, 2023, in New Orleans, LA. Key presentations include:
- Safety and Tolerability Study of CLS-AX in Neovascular AMD - April 23, 2023
- Suprachoroidal delivery of CLS-301 - April 25, 2023
- Early Adoption of Triamcinolone Acetonide Suprachoroidal Injection - April 25, 2023
Clearside's proprietary SCS Microinjector® allows targeted therapy delivery, potentially enhancing treatment efficacy while reducing toxicity. The investigational CLS-AX, a suspension of axitinib, is undergoing Phase 2 clinical testing for retinal diseases, promising prolonged and targeted delivery.
FAQ
What is the current stock price of Clearside Biomedical (CLSD)?
What is the market cap of Clearside Biomedical (CLSD)?
What does Clearside Biomedical, Inc. specialize in?
Where is Clearside Biomedical, Inc. located?
What is the SCS Microinjector®?
How does Clearside Biomedical's technology benefit patients?
What recent achievements has Clearside Biomedical reported?
Who can be contacted for investor and media inquiries?
What kind of presentations feature Clearside's technology?
What diseases is Clearside Biomedical targeting with their therapies?
Is Clearside Biomedical's procedure surgical?
What is the significance of Clearside's technology in ophthalmology?
